Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TOI Stock Summary
Top 10 Correlated ETFs
TOI
In the News
Down -23.64% in 4 Weeks, Here's Why The Oncology Institute (TOI) Looks Ripe for a Turnaround
The Oncology Institute (TOI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
The Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2023 financial results after the market close on Wednesday, March 27, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
Penny Stocks To Buy Now? 4 To Watch Before 2024
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
The Oncology Institute, Inc. (TOI) Q3 2023 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Jack Slevin - Jefferies Operator Good afternoon, and welcome to The Oncology Institute Third Quarter 2023 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.
The Oncology Institute Announces Third Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
The Oncology Institute Executive Leaders to Present at the 2023 Association for Value-Based Cancer Care (AVBCC) Summit
CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating in the Association for Value-Based Cancer Care (AVBCC) Summit.
The Oncology Institute, Inc. (TOI) Q2 2023 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Taji Phillips - Jefferies Operator Good afternoon ladies and gentlemen and welcome to The Oncology Institute's Second Quarter 2023 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.
The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
3 Penny Stocks That Have Game-Changing Technologies
The NASDAQ index led the market out of technical bear market territory. And if the rally is going to have legs, investors will know they have artificial intelligence ( AI ) to thank for it.
The Oncology Institute Announces First Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2023 financial results after the market close on Wednesday, May 10, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
TOI Financial details
TOI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.94 | 2.41 | 2.91 | 3.07 | 3.13 | |
Net income per share | 0.14 | -0.06 | -0.22 | -0.16 | 0.02 | |
Operating cash flow per share | 0.2 | 0.06 | 0.01 | -0.49 | -0.77 | |
Free cash flow per share | 0.17 | 0.04 | -0.01 | -0.54 | -0.83 | |
Cash per share | 0 | 0.04 | 0.09 | 1.73 | 0.92 | |
Book value per share | 0 | 0.66 | 0.44 | 1.57 | 1.55 | |
Tangible book value per share | 0 | 0.1 | -0.09 | 0.9 | 1.03 | |
Share holders equity per share | 0 | 0.66 | 0.44 | 1.57 | 1.55 | |
Interest debt per share | 0 | 0 | 0.19 | 0.01 | 1.39 | |
Market cap | 278.88M | 625.13M | 696.02M | 645.75M | 133M | |
Enterprise value | 0 | 622.68M | 701.95M | 531.63M | 227.17M | |
P/E ratio | 70.64 | -155.45 | -48.6 | -59.1 | 80.27 | |
Price to sales ratio | 2.46 | 4.02 | 3.71 | 3.18 | 0.53 | |
POCF ratio | 49.43 | 172.91 | 1.37K | -19.76 | -2.15 | |
PFCF ratio | 56.39 | 259.31 | -1.01K | -18.07 | -1.98 | |
P/B Ratio | 0 | 14.81 | 24.77 | 6.2 | 1.07 | |
PTB ratio | 0 | 14.81 | 24.77 | 6.2 | 1.07 | |
EV to sales | 0 | 4.01 | 3.74 | 2.62 | 0.9 | |
Enterprise value over EBITDA | 0 | 2.03K | -62.18 | -12.82 | -3.39 | |
EV to operating cash flow | 0 | 172.24 | 1.38K | -16.27 | -3.68 | |
EV to free cash flow | 0 | 258.3 | -1.02K | -14.88 | -3.38 | |
Earnings yield | 0.01 | -0.01 | -0.02 | -0.02 | 0.01 | |
Free cash flow yield | 0.02 | 0 | 0 | -0.06 | -0.51 | |
Debt to equity | 0 | 0 | 0.42 | 0 | 0.87 | |
Debt to assets | 0 | 0 | 0.18 | 0 | 0.41 | |
Net debt to EBITDA | 0 | -7.97 | -0.53 | 2.75 | -1.4 | |
Current ratio | 0 | 1.6 | 1.04 | 5.17 | 4.37 | |
Interest coverage | 3.01K | -780.67 | -23.62 | -143.31 | -17.64 | |
Income quality | 1.43 | -0.9 | -0.04 | 2.99 | -37.27 | |
Dividend Yield | 0.03 | 0 | 0 | 0 | 0 | |
Payout ratio | 2.08 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.61 | 0.51 | 0.22 | 0.16 | |
Capex to operating cash flow | -0.12 | -0.33 | -2.35 | 0.09 | 0.09 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | |
Capex to depreciation | -0.63 | -0.41 | -0.38 | -0.91 | -1.25 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.12 | 0.11 | |
Graham number | 0 | 0.96 | 1.48 | 2.42 | 0.85 | |
ROIC | 0 | -0.1 | -0.2 | -0.41 | -0.24 | |
Return on tangible assets | 0 | -0.17 | -0.45 | -0.07 | 0.01 | |
Graham Net | 0 | -0.03 | -0.26 | 0.52 | -0.38 | |
Working capital | 0 | 8.21M | 1.11M | 124.26M | 100.65M | |
Tangible asset value | 0 | 6.14M | -5.64M | 59.29M | 83.31M | |
Net current asset value | 0 | 4.49M | -7.87M | 54.78M | -8.56M | |
Invested capital | 0 | 0 | 0.42 | 0 | 0.87 | |
Average receivables | 0 | 0 | 16M | 19.25M | 30.88M | |
Average payables | 0 | 0 | 10.76M | 14.1M | 12.47M | |
Average inventory | 0 | 0 | 4.12M | 5.4M | 7.85M | |
Days sales outstanding | 0 | 34.61 | 33.59 | 38.2 | 58.58 | |
Days payables outstanding | 0 | 25.85 | 30.63 | 35.02 | 17.07 | |
Days of inventory on hand | 0 | 11.31 | 10.55 | 14.49 | 16.87 | |
Receivables turnover | 0 | 10.55 | 10.87 | 9.56 | 6.23 | |
Payables turnover | 0 | 14.12 | 11.91 | 10.42 | 21.38 | |
Inventory turnover | 0 | 32.26 | 34.6 | 25.19 | 21.64 | |
ROE | 0 | -0.1 | -0.51 | -0.1 | 0.01 | |
Capex per share | -0.02 | -0.02 | -0.02 | -0.05 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.82 | 0.83 | 1.04 | 1.1 | 1.12 | |
Net income per share | -0.03 | -0.11 | -0.41 | -0.23 | -0.24 | |
Operating cash flow per share | -0.26 | -0.16 | -0.21 | -0.12 | -0.11 | |
Free cash flow per share | -0.27 | -0.19 | -0.24 | -0.13 | -0.13 | |
Cash per share | 1.14 | 0.86 | 0.75 | 0.54 | 1.19 | |
Book value per share | 1.61 | 1.46 | 1.34 | 1.16 | 0.98 | |
Tangible book value per share | 0.98 | 0.97 | 1.04 | 0.8 | 0.63 | |
Share holders equity per share | 1.61 | 1.46 | 1.34 | 1.16 | 0.98 | |
Interest debt per share | 1.35 | 1.29 | 1.53 | 1.64 | 1.63 | |
Market cap | 368.46M | 141.23M | 49.79M | 40.02M | 102.86M | |
Enterprise value | 413.1M | 235.4M | 144.58M | 127.46M | 192.67M | |
P/E ratio | -34.45 | -3.72 | -0.41 | -0.59 | -1.48 | |
Price to sales ratio | 5.67 | 1.98 | 0.65 | 0.5 | 1.25 | |
POCF ratio | -18.06 | -10.09 | -3.22 | -4.62 | -12.38 | |
PFCF ratio | -17.07 | -8.83 | -2.88 | -4.17 | -11.13 | |
P/B Ratio | 2.88 | 1.13 | 0.51 | 0.47 | 1.43 | |
PTB ratio | 2.88 | 1.13 | 0.51 | 0.47 | 1.43 | |
EV to sales | 6.36 | 3.3 | 1.9 | 1.59 | 2.35 | |
Enterprise value over EBITDA | -21.74 | -17.74 | -10.8 | -9.86 | -16.86 | |
EV to operating cash flow | -20.25 | -16.82 | -9.36 | -14.72 | -23.19 | |
EV to free cash flow | -19.13 | -14.72 | -8.36 | -13.28 | -20.85 | |
Earnings yield | -0.01 | -0.07 | -0.6 | -0.42 | -0.17 | |
Free cash flow yield | -0.06 | -0.11 | -0.35 | -0.24 | -0.09 | |
Debt to equity | 0.83 | 0.87 | 1.12 | 1.37 | 1.63 | |
Debt to assets | 0.37 | 0.41 | 0.47 | 0.51 | 0.54 | |
Net debt to EBITDA | -2.35 | -7.1 | -7.08 | -6.76 | -7.86 | |
Current ratio | 4.37 | 4.37 | 3.95 | 3.11 | 4.71 | |
Interest coverage | -13.42 | -6.18 | -6.04 | -5.59 | -5.17 | |
Income quality | 7.63 | 1.47 | 0.52 | 0.51 | 0.48 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.18 | 0.16 | 0.09 | 0.12 | 0.12 | |
Capex to operating cash flow | 0.06 | 0.14 | 0.12 | 0.11 | 0.11 | |
Capex to revenue | -0.02 | -0.03 | -0.02 | -0.01 | -0.01 | |
Capex to depreciation | -1.05 | -1.67 | -1.45 | -0.71 | -0.55 | |
Stock based compensation to revenue | 0.1 | 0.08 | 0.07 | 0.05 | 0.06 | |
Graham number | 1.1 | 1.91 | 3.51 | 2.47 | 2.28 | |
ROIC | -0.08 | -0.06 | -0.07 | -0.06 | -0.06 | |
Return on tangible assets | -0.01 | -0.04 | -0.14 | -0.08 | -0.09 | |
Graham Net | -0.42 | -0.35 | -0.56 | -0.89 | -0.22 | |
Working capital | 110.78M | 100.65M | 88.88M | 70.57M | 120.29M | |
Tangible asset value | 78.25M | 83.31M | 76.63M | 58.15M | 46.06M | |
Net current asset value | -12.24M | -8.56M | -17.27M | -41.17M | 6.18M | |
Invested capital | 0.83 | 0.87 | 1.12 | 1.37 | 1.63 | |
Average receivables | 32.37M | 37.95M | 43.45M | 46.64M | 47.9M | |
Average payables | 12.53M | 10.26M | 10.66M | 12.53M | 13.23M | |
Average inventory | 9.3M | 9.64M | 9.76M | 11.21M | 12.17M | |
Days sales outstanding | 49 | 51.06 | 54.79 | 52.61 | 53.65 | |
Days payables outstanding | 19.32 | 15.12 | 17.31 | 18.14 | 18.17 | |
Days of inventory on hand | 17.35 | 14.94 | 14.86 | 16.82 | 16.59 | |
Receivables turnover | 1.84 | 1.76 | 1.64 | 1.71 | 1.68 | |
Payables turnover | 4.66 | 5.95 | 5.2 | 4.96 | 4.95 | |
Inventory turnover | 5.19 | 6.02 | 6.06 | 5.35 | 5.43 | |
ROE | -0.02 | -0.08 | -0.3 | -0.2 | -0.24 | |
Capex per share | -0.01 | -0.02 | -0.03 | -0.01 | -0.01 |
TOI Frequently Asked Questions
What is The Oncology Institute, Inc. stock symbol ?
The Oncology Institute, Inc. is a US stock , located in Cerritos of Ca and trading under the symbol TOI
Is The Oncology Institute, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $8. The lowest prediction is $6 and the highest is $10
What is TOI stock prediction ?
What is The Oncology Institute, Inc. stock quote today ?
The Oncology Institute, Inc. stock price is $1.545 today.
Is The Oncology Institute, Inc. stock public?
Yes, The Oncology Institute, Inc. is a publicly traded company.